By continuing to view this video or podcast, you confirm that you are a healthcare professional. Mundipharma owns all rights, including copyrights, to this recording. The recording (or any link to it) may not be changed, supplemented or redistributed without the express written consent of Mundipharma.

Is point-of-care testing a solution to early diagnosis of invasive fungal infections?

In June 2023, Patricia Muñoz, Martin Hoenigl and Malgorzata Mikulska came together to discuss the patient groups who benefit from point-of-care testing, as well as the challenges of implementing this type of testing. The use of T2Candida^® to diagnose patients with candidemia was also explored.

SciA-AFN-2400015 | February 2024

Is point-of-care testing a solution to early diagnosis of invasive fungal infections?

In June 2023, Patricia Muñoz, Martin Hoenigl and Malgorzata Mikulska came together to discuss the patient groups who benefit from point-of-care testing, as well as the challenges of implementing this type of testing. The use of T2Candida® to diagnose patients with candidemia was also explored.

Reporting adverse events

In June 2023, Patricia Muñoz, Martin Hoenigl and Malgorzata Mikulska came together to discuss the patient groups who benefit from point-of-care testing, as well as the challenges of implementing this type of testing. The use of T2Candida^® to diagnose patients with candidemia was also explored.